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Abstract—Photosensitizers (PSs) have shown great potentials
as molecular contrast agents in photodynamic diagnosis
(PDD) of cancer. While the diagnostic values of PSs have
been proven previously, little efforts have been put into
developing optical imaging and diagnostic algorithms. In this
article, we review the recent development of optical probes
that have been used in conjunction with a potent PS,
hypericin (HY). Various ﬂuorescence techniques such as laser
confocal microscopy, ﬂuorescence urine cytology, endoscopy
and endomicroscopy are covered. We will also discuss about
image processing and classiﬁcation approaches employed for
accurate PDD. We anticipate that continual efforts in these
developments could lead to an objective PDD and complete
surgical clearance of tumors. Recent advancements in nano-
technology have also opened new horizons for PSs. The use
of biocompatible gold nanoparticles as carrier for enhanced
targeted delivery of HY has been attained. In addition,
plasmonic properties of nanoparticles were harnessed to
induce localized hyperthermia and to manage the release of
PS molecules, enabling a better therapeutic outcome of a
combined photodynamic and photothermal therapy. Finally,
we discuss how nanoparticles can be used as contrast
agents for other optical techniques such as optical coher-
ence tomography and surface-enhanced Raman scattering
imaging.
Keywords—Hypericin, Photodynamic diagnosis, Fluores-
cence, Endoscopy, Urine cytology, Endomicroscopy, Gold
nanoparticle, Photothermal therapy.
INTRODUCTION
Successful detection of cancer onset and surgical
clearance of tumor certainly help to increase the rate of
survival without recurrence.
60,62 Current diagnosis and
surgical procedures depend largely on visual inspection
using a primitive white-light endoscope (WLE). How-
ever, the given diagnostic information about the tissue
has always been inadequate for an objective assessment
that has a decisive impact on the therapeutic outcome.
Many optical techniques
82,94,101,103 are capable of
acquiring rich diagnostic information and signaling
any subtle changes occurring in tissue optics and bio-
chemistry. These imaging techniques, therefore, pro-
vide a means of visualizing the structural and
molecular contrast between healthy and cancerous
tissues. This visual aid can potentially be a useful
adjunct to complete resection of multifocal tumors.
While these optical diagnostic techniques are typi-
cally used in research laboratories, some of which are
being translated to clinical practice.
4,28,59,88 Advance-
ments in ﬁber optics, optoelectronics, and microactu-
ators have provided cost-effective solutions to the
integration of these optical diagnostics into an existing
catheter or endoscope that is being used as a naviga-
tion aid in standard diagnosis. Regardless of the
techniques used, the measured optical signals are
essentially correlated with the pathological status of
the tissues that can vary the light-tissue interactions
by light absorption, scattering, and emission. The
acquired data, in general, is overwhelming, and thus
needs to be modeled and condensed into a set of
concise diagnostic parameters from which a diagnostic
algorithm can be derived to perform a light-guided
biopsy and surgery.
Photosensitizers (PSs) are light-triggered drugs
specially used in photodynamic therapy (PDT) to
eradicate cancerous cells.
16 PSs are also ﬂuorescent
compounds with preferential uptake by tumors. These
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460attributes make PS a promising biomarker to diagnose
cancer using ﬂuorescence techniques. Such optical
diagnoses are now commonly referred to as photody-
namic diagnosis (PDD). PDD of cancer has found
its way into widespread clinical use, and the diag-
nostic values of PDD agents have already been
reviewed.
33,34,44 While the photosensitizing and chem-
ical properties of PSs have been much studied,
37 less
emphasis is given to the probe design and diagnostic
algorithms that also have an impact on the diagnostic
accuracy. A fair evaluation of these aspects among
different groups is usually difﬁcult because the diag-
nostic outcomes depend on several factors including
cancer types, PS administration, and formulation. In
this review article, we narrow our focus to discussion
on PDD using hypericin (HY), a potent PS, which our
group has been investigating with customized instru-
ments and diagnostic algorithms developed to aid
quantitative and objective analysis. In addition to the
diagnostic values from HY ﬂuorescence, our group
also attempts to couple HY with nanoparticles to
extend its use in other optical imaging techniques.
This review is divided up as follows: First, PDD of
cancer using PSs is discussed and compared with
autoﬂuorescence diagnosis. Second, the ﬂuorescence
properties of HY and issues surrounding its solubility
and targeted delivery are presented. Third, studies of
HY-PDD used with assorted ﬂuorescence diagnostic
devices are detailed; this section highlights the recent
development of optical instruments and diagnostic
algorithms for directing biopsies and assessing resec-
tion margins for lesions. While HY is widely used in
PDD and PDT, its use can be further extended to other
regimes. The following section summarizes the
underlying trend in nanotechnology that gradually
reinforces the use of HY for combined therapeutics
and multimodality imaging.
FLUORESCENCE DIAGNOSIS OF CANCER
Fluorescence diagnosis of cancer utilizes the char-
acteristic ﬂuorescence signatures, either from inherent
or exogenous ﬂuorophores, to distinguish abnormal
tissues from surrounding normal tissues. If the ﬂuo-
rescence signatures of inherent biomolecules are uti-
lized, then the diagnostic technique is termed as
Autoﬂuorescence diagnosis, and Exogenous ﬂuores-
cence diagnosis, if exogenous ﬂuorophores are used.
Autoﬂuorescence Diagnosis
Successful autoﬂuorescence diagnosis has been pre-
viously reported to distinguish normal from malignant
tissues. For instance, Koenig et al.
49 conducted cancer
diagnosis by comparing the autoﬂuorescence spectra of
the tissues excited at 337 nm. By calculating the ﬂuo-
rescence intensity ratios at 385 and 455 nm, the auto-
ﬂuorescence signal from collagen and reduced
nicotinamide adenine dinucleotide (NADH), respec-
tively, the study could discern normal and malignant
lesions with sensitivity and speciﬁcity of 97 and 98%,
respectively. Another autoﬂuorescence study by Zaak
et al.,
108—using different intensity ratios at 335 and
430 nm, corresponding to signals from tryptophan-rich
proteins and NADH, respectively—distinguished
malignant from benign lesions with sensitivity and
speciﬁcity of 95 and 77%, respectively. Similarly,
ﬂuorescence endoscopy has also been utilized in dis-
cerning normal from cancerous lesions, where the
extent of loss in autoﬂuorescence emission in the green
region of the visible spectrum was considered the dis-
tinguishing parameter.
51,70
However, most of these endogenous ﬂuorophores
weakly ﬂuoresce even when excited optimally at
UV-blue region (300–450 nm). In addition, the penetration
depth of UV-blue light in tissue is often limited by high
tissue scattering and strong absorption of hemoglobin
in 400–500 nm region.
69 The epithelial thickening,
which typically occurs in tumors, can further reduce
the amount of excitation light reaching the inner sub-
mucosa where most endogenous ﬂuorophores are
located. The failure in probing the ﬂuorescence emis-
sion from deeper layers presented limitation in distin-
guishing carcinoma from dysplasia and carcinoma
in situ (CIS).
11,51
Exogenous Fluorescence Diagnosis
Exogenous ﬂuorescence diagnosis uses synthetic
ﬂuorophores, which are excitable at longer wavelength,
to visualize neoplastic lesions that cannot be seen using
white-light imaging and autoﬂuorescence imaging.
Unlike autoﬂuorescence, exogenous ﬂuorescence diag-
nosis relies on positive ﬂuorescence staining of malig-
nant and pre-malignant lesions. This reﬂected in
increased detection of dysplasia and CIS, and dis-
cerning of these from malignant tumors.
34,102 Cur-
rently, the exogenous ﬂuorophores used in clinical
environment are PS. PSs are compounds that, along
with ﬂuorescing capability, have favorable diagnostic
characteristics, such as tumor speciﬁcity, rapid phar-
macokinetic elimination, low levels of dark-toxicity,
etc.
6 HY, 5-aminolevulinic acid (ALA) and its deriva-
tives, like 5-ALA hexylester, are prominent among PSs
that are being evaluated for its clinical utility. These
PSs are traditionally used in PDT for its aforemen-
tioned properties, and when used for diagnostic pur-
poses, the technique is termed as PDD. PDD, as an
alternative diagnostic technique, has already been
New Frontier in Hypericin-Mediated Diagnosis of Cancer 461approved for bladder cancer in European Union (EU)
and European Economic Area (EEA).
11,109
Ideal Photodynamic Diagnosis Agent
5-aminolevulinic acid is a PS that induces and
accumulates ﬂuorescent protoporphyrin IX (PpIX),
and was initially reported by Kennedy et al.
45 and
Kreigmair et al.
34 Though 5-ALA was widely investi-
gated, it faced shortcomings like fast photobleaching
of induced PpIX and less tissue penetration due to low
lipophilicity and lower speciﬁcity. Subsequently, vari-
ous derivatives of 5-ALA were also investigated with
little success. Then D’Hallewin et al.
12 identiﬁed HY as
a better choice of PS used for detecting bladder cancer.
Though the diagnosis with 5-ALA (78–100%) has
sensitivity comparable to HY (82–94%),
75 it was
shown to yield low speciﬁcity ranging from 41 to
66%,
34 which implies many false positives. On the
other hand, studies that investigated HY for ﬂuores-
cence diagnosis reported excellent sensitivity along
with superior speciﬁcity ranging from 91
81 to 98%,
12
which greatly reduces the incidence of false positive
results. Later studies continue to report HY’s advan-
tages over other drugs, in ﬂuorescence diagnosis and
PDT
87 of various cancers.
51,56,64,89,109,111
PHOTODYNAMIC PROPERTIES
OF HYPERICIN
Fluorescence Properties
Hypericin is extracted from a plant, Hypericum
perforatum L., commonly known as St. John’s Wort.
HY consistently exhibited well-resolved spectral bands
when dissolved in various organic solvents, with
absorption maxima at around 540 and 590 nm,
and ﬂuorescence maxima at around 590 and
640 nm.
11,97,100 Absorption maxima of HY being at
longer wavelength allows excitation light to reach HY
in deeper tumors whereas light that excites 5-ALA-
induced PpIX with absorption maxima at around
400 nm can only penetrate shallowly into tissue.
Another important property of HY making it a prime
PS in PDD is its photostability, as reported by various
studies, and its ﬂuorescence could be detected for up to
16 h after instillation. Its photostability could be fur-
ther enhanced when formulated with 40% N-methyl
pyrrolidone (NMP).
77
Tumor Selectivity of Hypericin
Despite the fact that HY exhibits tumor selectivity,
the speciﬁc mechanism involving the cellular uptake is
yet to be fully understood. The possible mechanism of
preferential HY accumulation in cancerous cells has
been reviewed elsewhere.
78 In brief, it has been pro-
posed that both diffusion and endocytosis contribute
to the overall transport of HY into individual cancer-
ous cells.
78 Olivo et al.
66 showed that HY indeed
preferentially localizes in the tumor and the intensity of
microscopic HY ﬂuorescence increased with both stage
and histological grade of bladder cancer. For instance,
the HY intensity of grade 3 cancerous cells was shown
to be nearly 3 times higher than of grade 1 cells.
In addition to the fact that intracellular uptake of
HY is higher in cancerous cells, subsequent studies
unraveled other possible contributing factors to its
selective accumulation at tissue level.
30,68 For instance,
Huygens et al.
30 studied human bladder cell carcinoma
using a 3-dimensional (3D) spheroid model, and
reported that the loss in intercellular adhesion due to
the reduced expression of a transmembrane adhesion
protein, E-cadherin, plays a pivotal role in the selective
uptake of HY. Later, Olivo et al.
68 conducted further
studies to evaluate the expression of other cell-adhe-
sion molecules (E-cadherin, a-catenin, b-catenin, and
c-catenin) in histologically graded biopsies obtained
after intravesical instillation of HY. In particular,
using immunoﬂuorescence staining, E-cadherin expres-
sion was found to decrease in proportion to both the
tumor grade as well as the depth of invasion. In
addition, mRNA analysis showed that expression of
E-cadherin and b-catenin was down regulated in high-
grade urothelial cell carcinoma (UCC), modifying the
histoarchitecture in bladder tumor and decreasing the
epithelial paracellular barrier function. This eventually
leads to enhanced paracellular diffusion of HY into
the deeper layers of tissue before intracellular uptake.
Hence, stronger HY ﬂuorescence in the UCC was
observed with increased grade and advanced stage.
The ﬂuorescence imaging showed that the HY intensity
of grade 1, 2, and 3 tissues was approximately 5.4, 8.4,
and 10.4 times greater than that of normal bladder
tissues.
68
Solubility and Delivery
Hypericin is a lipophilic compound that forms
aggregates and sparingly dissolves in aqueous solution.
Diﬀerent solvents have been tried to overcome this
hydrophobicity of HY. These include organic solvents,
such as ethanol, tetrahydrofuran, and acetone, and
also serum proteins which are reported to dissolve
most hydrophobic compounds.
34,74,76,100 Therefore,
the focus of recent studies by research groups involved
in ﬂuorescence diagnosis of cancer is directed toward
new formulations to be used with HY, like using
Solketal as absorption enhancer,
42 polyvinylpyrroli-
done (PVP)
93 and cyclodextrins as solubilizers,
78 and
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76 For example, our lab
investigated HY formulated with different concentra-
tions of NMP and found effective solubilizing and
delivery of HY to the target site, bladder urothelium in
this study.
77 Subsequently, our in vitro study with
MGH cell line and in vivo studies showed that HY with
0.05% NMP yielded optimal uptake and cell survival.
Its delivery efﬁcacy was found to be superior to HY
with human serum albumin, which is being clinically
used for PDD.
76,101 However, further studies are
warranted to determine the optimal concentration of
NMP, which solubilizes HY and enhances its tissue
penetration without compromising uptake and cell
survival.
HYPERICIN-MEDIATED PDD OF CANCER
WITH VITAL FLUORESCENCE
TECHNOLOGIES
D’Hallewin et al.
12 ﬁrst reported the clinical use of
HY-induced PDD in detecting ﬂat CIS lesions of
bladder. Thereafter, studies of HY mostly focused on
the detection of bladder cancer.
14,43,81 Apart from
bladder screening, the applications of HY were also
extended to diagnosing other types of cancers includ-
ing oral cancer
88 and stomach cancer.
15,58 The fol-
lowing sub-sections will mainly discuss about the
development of instrumentation and data processing
for HY-PDD of bladder and oral cancer.
Microscopic Fluorescence Studies and Diagnosis
FollowingthepilotstudyofHY-PDDbyD’Hallewin
et al.,
12 Olivo et al.
66 investigated the microscopic ﬂuo-
rescence properties of HY in human bladder cancer.
Spectroﬂuorometric study of the bladder cancer cell
lines revealed rapid uptake of HY as early as 15 min
from incubation, and fast clearance from cells within
48 h. Maximum ﬂuorescence intensity was detected
between 2 and 3 h, and this determined the optimum
intravesicalinstillationtimeofHYforscreeningbladder
cancer using a ﬂuorescence endoscope (FE). A clinical
evaluation was then carried out with 30 patients com-
paring FE with conventional WLE. Under blue-light
illuminationusingFE,ﬂuorescence emission ofHYwas
induced, andbiopsies were taken from thoseﬂuorescent
regions for microscopic ﬂuorescence analysis and his-
topathological grading (see Fig. 1). With the aid of a
laser confocal microscopy (LCM), the HY retained in
thetissueswasopticallyexcitedat488 nm,andadistinct
ﬂuorescence distribution across the tissue section was
observed from the transitional cell carcinoma (TCC)
and CIS lesions. The intensity of the microscopic HY
ﬂuorescence increased with both stage (Ta, T1, and T2),
and histological grade of bladder cancer (G1–G3), as
showninFig. 2.Inparticular,thisPDDmethodenabled
anearlydetectionofCISandotherﬂatlesions,whichare
frequently overlooked due to poor contrast given by
WLE. These microscopic studies evidenced that PDD
with HY could be used as a diagnostic aid to conven-
tional histopathology. These microﬂuorescence prop-
erties of HY were later utilized in ﬂuorescence urine
cytology.
Ex Vivo Urine Cytology
White-light endoscope combined with random
biopsy has been the gold standard for a deﬁnitive
diagnosis of bladder tumors. However, the examina-
tion procedure is time-consuming and is associated
with patient discomfort. Thus, a non-invasive and
FIGURE 1. The distinct contrast between (a) white-light and (b) ﬂuorescence endoscopic imaging of TCC after instillation with
HY. The red ﬂuorescence region in (b) indicates the presence of TCC (Reproduced with permission of International Journal of
Oncology
66.).
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ogy, is highly desirable. Urine cytology is an ex vivo
screening technique that analyzes the exfoliated blad-
der cells from voided urine. While this technique is
suitably used for detecting CIS, it has low sensitivity in
identifying early or low grade bladder cancer.
18,65
Olivo et al.
65 has therefore undertaken a pilot study of
using ex vivo ﬂuorescence cytology for detecting early
bladder cancer. Similar study has been demonstrated
using 5-ALA, but such diagnosis required urine col-
lection following instillation of 5-ALA in bladder of
patients.
86 On the other hand, we have demonstrated a
biopsy-free screening technique that combines the
advantages of PDD and urine cytology even without
the need for intravesical instillation of HY. In brief, the
urine samples were processed to extract the exfoliated
bladder cells before incubating the cells with HY
solution for a ﬁxed duration of time. A LCM (Carl
Zeiss, LSM 510) coupled with a spectrometer was used
to quantify the ﬂuorescence intensity of the HY-treated
cells excited at 488 nm. In line with the in vitro cell lines
studies,
66 the exfoliated abnormal bladder cells exhib-
ited stronger HY ﬂuorescence compared to normal
bladder cells, as shown in Fig. 3. Subsequently, Fu
et al.
18 extended the ﬂuorescence urine cytology by
expanding the sample size and automating the ﬂuo-
rescence analysis of each single cell. Advanced image
processing techniques were implemented to ﬁrst single
out bladder cells for image analysis and to eliminate
the signals from other urinary components such as red
blood cells and crystalline contaminants. The intensity
histograms were then extracted from the processed
images and the ﬁrst three moments were derived to
represent the image data. Figure 3 depicts the different
histogram proﬁles of the urothelial cells. Subsequently,
Bayes classiﬁcation technique was carried out to clas-
sify targeted cells based on the derived moments. The
results showed that the discrimination between benign
cells and low-grade tumor cells is very promising, with
sensitivity and speciﬁcity above 90%. Furthermore, its
diagnostic performance is found to surpass that of
conventional urine cytology. To this end, the ﬁndings
suggest that the ex vivo ﬂuorescence urine cytology
using HY provide a non-invasive means of detecting
the early bladder cancer.
Fluorescence Endoscopy
Currently, oral cancer and bladder cancer are diag-
nosed by examination under WLE followed by random
biopsies on suspicious-looking tissues and histological
examination of the biopsies. Histopathological exami-
nation of biopsy tissue remains the gold standard for
deﬁnitive diagnosis. However, this approach to make
diagnosis presents at least two key limitations. First,
earlyﬂatoralorbladderlesionsarehardlyvisible,andit
is diﬃcult to distinguish between benign and early can-
cer.
9,88 Poor visual contrast in WLE therefore necessi-
tatesarandomsamplingoftissues,butstillrisksmissing
the lesion and gives false negative results.
3 Additional
biopsies could also cause unnecessary suffering to
patients. Needless to say, a complete surgical clearance
would also be difﬁcult. Second, tissue processing is
FIGURE 2. Increased HY intensity from (a) normal bladder, (b) TCC grade 1, and (c) TCC grade 2 to (d) CIS when excited at 488 nm
(Reproduced with permission of International Journal of Oncology
66.).
FIGURE 3. Typical histogram data from the processed ﬂuo-
rescence images of normal (h), low-grade tumor (s), high-
grade tumor (D), and inﬂammatory (3) bladder classes.
(Reproduced with permission of International Journal of
Oncology
18.) Inset shows the typical image of TCC urothelial
cells obtained with ﬂuorescence urine cytology (Reproduced
with permission of International Journal of Oncology
65.).
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The histopathological examination also relies on sub-
jective visual impression from clinicians. It is therefore
of interest to develop novel imaging techniques that can
provide objective and accurate diagnosis without the
need for tissue resection.
Following the earlier statement that PSs accumulate
selectively in abnormal cells, the microscopic ﬂuores-
cence analysis was extended to macroscopic endo-
scopic images. FE was used to highlight lesions from
which the PS ﬂuorescence is emitted when excited by
light at appropriate wavelength. Several groups have
explored PSs that were suitably used in ﬂuorescence
endoscopy in an attempt to overcome the shortcom-
ings of WLE.
73,80,106,112 To date, a number of review
articles are available to compare the efﬁcacy of dif-
ferent PSs for detecting bladder tumor.
33,34,44,60 A
comparison of their diagnostic performance is thus not
reviewed here. In essence, the mean value of the sen-
sitivity for FE is 93% compared to only 73% for
WLE.
34 The increase in diagnostic sensitivity (82% for
HY vs. 62% for white-light) compared to WLE has led
to use of HY in ﬂuorescence-guided biopsies to mini-
mize unnecessary biopsies.
81
Fluorescence endoscope is often merged with the
existing WLE system that facilitates clinicians to
position the imaging probe and to sample the tissue for
any further diagnosis.
107 Figure 4a depicts a typical FE
system (Karl Storz Endoscope, Germany) that was
custom-built to directly visualize lesions after intra-
vesical instillation of HY for routine diagnosis as well
as surgical procedures.
88,112 Ideally, a FE system was
designed to irradiate the PS with excitation ﬁlter chosen
to exactly match its absorption peak. Subsequently, the
resulting ﬂuorescence emission was speciﬁcally ﬁltered
for sole detection of PS ﬂuorescence. The imaging
system in Fig. 4a was equipped with a xenon short arc
lamp for white-illumination. HY ﬂuorescence was
induced when the excitation light was ﬁltered by a
bandpass ﬁlter (380–440 nm), whereas the emitted
ﬂuorescence signal was ﬁltered by a long-pass (LP)
ﬁlter (cut-off wavelength at 480 nm) before reaching
the CCD camera. This observation LP ﬁlter transmit-
ted 8% of the backscattered excitation light at 450 nm,
while it had a transmission of over 98% in the 470–
800 nm. The marginal detection of the excitation light
was in fact useful to eliminate variations due to day-
to-day intensity ﬂuctuations of the excitation source
and to calibrate the probe-to-tissue distance.
112 The
endoscopy was ﬁnally interfaced to a PC for image
acquisition and ﬁnal analysis.
The acquired ﬂuorescence images were ﬁrst pre-
processed to extract the region-of-interest (ROI) or the
approximated region of lesion based on hue thres-
holding, as shown in Figs. 4b and 4c). The calculated
hue histogram showed a bimodal distribution, with
two peaks indicating the ﬂuorescence characteristics of
HY and healthy tissue, respectively. In relation to the
preferential accumulation of HY in tumor, hue thres-
holding at global minimum was found to be effective in
estimating the tumor margin.
39 Diagnostic parameters
of the segmented images, i.e., the ROIs, were then
extracted and expressed in terms of the red (IR), green
(IG), and blue (IB) intensity values (RGB), as well as
the hue, saturation, and intensity (HSI) values.
88,107
The result showed that the red-to-blue intensity ratio
(IR/IB) was the best image parameter for discriminating
normal from hyperplastic tissues with the sensitivity
FIGURE 4. (a) A ﬂuorescence endoscopy system interfaced to a PC-based image acquisition and analysis system for ﬂuores-
cence diagnostic imaging. (Reproduced with permission of British Journal of Cancer
88.) (b) Under blue-light excitation, the
autoﬂuorescence of healthy tissue and HY ﬂuorescence of cancerous tissue can be clearly discerned. (c) The system is also
capable of deﬁning the AOI where the tumor is localized for ﬂuorescence analysis (Reproduced with permission of Lasers in
Surgery and Medicine
39.).
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from squamous-cell carcinoma (SCC) tissues with
sensitivity and speciﬁcity of 100%, respectively; and
hyperplastic from SCC with 92 and 90%, respec-
tively.
88 The discerning of normal tissue from hyper-
plastic and the SCC tissues by difference in red-to-blue
intensity (IR/IB)a si nFig. 5. The IR corresponded to
the HY ﬂuorescence intensity, indicating a selective
uptake amount of HY in lesions; on the other hand,
the backscattered blue excitation light contributed to
the IB. Furthermore, the diagnostic accuracy could be
elevated by multivariate analysis. For instance, com-
bining the two ratio diagnostic algorithms (IR/IG vs.
IR/IB) was shown to yield diagnostic accuracy
exceeding those from each diagnostic algorithm
alone.
112 Using a high-speed computing platform, a
prototype of the real-time imager was developed to
automate delineation of ROI, system calibration and
immediate tissue classiﬁcation based on previously
developed algorithms. This integrated system thus not
only provided a diagnostic prediction and immediate
feedback for clinicians, but also offered surgeons a
visual aid for demarcation of tumor margin needed in
a precise surgical resection.
88
Real-Time 3D Endomicroscopy
To take this HY-mediated ﬂuorescence endoscopy
platform further, our group developed an embedded,
real-time computing system interfaced with a confocal
laser endomicroscopy (CLE) for 3D visualization of
tumors.
90 CLE has been applied for autoﬂuorescence
diagnostic imaging in gastroenterology,
20,29,46,71 gyne-
cology,
85 urology,
83 human oral, and oropharyngeal
mucosa.
23 A CLE offers imaging capabilities for in vivo
ﬂuorescence imaging of tissue structures from the
surface to a few hundred micrometers beneath the
surface.
17,46 This sub-surface imaging has been found
useful to detect malignancy by means of the altered
tissue architecture and irregularities in blood vessels.
23
Figure 6a illustrates the setup of a CLE (Optiscan,
Australia) that encompasses the 488-nm-laser, optical
ﬁlters, and lenses to image HY-ﬂuorescence from the
tissues. Similar setup was also reported by D’Hallewin
et al.,
13 for detecting the differences in ﬂuorescence
intensity and morphology of the epithelial cells. The
single-mode ﬁber enclosed in the rigid probe was mo-
vable to collect ﬂuorescence signal at different focal
planes, thereby capable of probing HY amount as a
function of tissue depth. Images were acquired with a
ﬁeld of view of 475 by 475 lm and a lateral resolution
of 0.7 lm. The image depth was about 250 lm,
depending on scattering and absorption properties of
tissue under investigation. Consecutive images of a
murine tongue were acquired at different tissue layers
following topical application of HY (see Fig. 6b). We
have further developed CLE by interfacing the probe
to a high-performance computing system.
10 This pro-
totype enabled a real-time 3D ﬂuorescence visualization
realized through programming a Field-Programmable
Gate Array (RC340 FPGA, Mentor Graphics Corpo-
ration, USA) board. The 3D visualization of a tissue
FIGURE 5. White-light and HY-induced ﬂuorescence images of normal (a, d), hyperplastic (b, e) and SCC tissues (c, f). Pro-
gressive increase in IR/IB ratio can be seen from normal to hyperplastic to SCC lesions (Reproduced with permission of British
Journal of Cancer
88.).
MALINI et al. 466can be reconstructed from a stack of ﬂuorescence
images acquired as demonstrated in Fig. 6b.
91 The
results showed that distinct 3D structures in the murine
tongue can be visualized and demonstrated the
potential of 3D endomicroscopy for diagnostic imaging
of the oral cavity. Unlike the aforementioned ﬂuores-
cence endoscopy, this approach gives additional diag-
nostic information about the tissue structure. With the
3D diagnostic images, the HY ﬂuorescence signals can
be fully used to enhance the morphological differences
between normal and diseased tissue. Likewise, it is
possible to examine the blood vessel architecture that is
associated with cancer development. However, extra-
neous light absorption and scattering from turbid tissue
is always inevitable, and a proper recovery of ﬂuores-
cence signal is thus necessary to accurately quantify the
concentration of HY. For instance, Xie et al.
99 have
presented the use of Monte Carlo simulation to effec-
tively compensate the light-attenuation for corrected
ﬂuorescence images. We thus anticipate that a real-time
3D endomicroscopy system coupled with recovery
algorithm can complement WLE and FE in a clinical
setting by providing the morphological details.
COUPLING WITH NANOTECHNOLOGY FOR
COMBINATORIAL THERAPEUTIC AND
MULTIMODALITY IMAGING
Traditionally, PSs are solely used for PDT in cancer
treatment, and their inherent ﬂuorescence properties
are utilized to aid diagnosis as discussed in previous
section. However, the recent advancements in nano-
technology opens up new horizon for PSs to be applied
in entirely diﬀerent ways. A short review is presented
here to highlight the possibility of developing nano-
construct integrated with HY for combinatorial ther-
apeutic and multimodality imaging.
Enhanced Targeted Delivery
As with most PSs, HY has limited water solubility
that makes systemic administration problematic and,
in turn, aﬀects its delivery to and uptake by tumor
cells.
50,52 Many efforts are ongoing to formulate better
PSs, but the pharmaceutical preparation is difﬁcult,
7
and issues associated with dark cytotoxicity and deﬁ-
cient in vivo selectivity are yet to be solved.
72 This has
FIGURE 6. (a) An endomicroscope interfaced with a Field Programmable Gated Array (FGPA) board designed for automated real-
time 3D imaging and reconstruction of ﬂuorescent samples. The movable single-mode ﬁber enclosed in the handheld probe was
used to collect ﬂuorescence signal emitted from different tissue depths. (Reproduced with permission of Journal of Biomedical
Optics
89.) (b) Six consecutive images were measured from different depths of the murine tongue following topical application of
HY. A 3D image was later reconstructed from those images and was displayed in pseudo-color (Reproduced with permission of
Journal of Medical Imaging and Health Informatics
91.).
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now equipped with nanocarrier systems to enhance
their targeted delivery for efﬁcient PDT and PDD.
35
These nanocarriers, which load PSs by adsorption or
covalent binding, offer beneﬁts of hydrophilicity and
appropriate size for passive targeting of tumor by the
enhanced permeability and retention (EPR) effect.
7 To
enhance accumulation, instead of reformulating the
PSs, the surface of carriers is functionalized for active
receptor-mediated targeting. Various types of nano-
carriers are available and their use in PDT has been
extensively reviewed. In particular, gold nanoparticles
(GNPs), such as spherical gold nanoparticles
(SGNPs)
61,67 and gold nanorod (GNRs),
53,96,105 are in
favor as PS carriers due to their biocompatibility, easy
preparation, efﬁcient bioconjugation, and high-drug
loading capacity.
25 GNPs are usually shielded with
polyethylene glycol (PEG) for prolonged circulation
time in the body.
63 Such GNPs are thus ideal plat-
form for delivering hydrophobic HY to tumor site,
with minimal damage to the normal tissue (See
Fig. 7a).
2,84,104 For instance, anti-EGFR-labeled
HY-SGNP was used to target EGFR-overexpressing
A-431 cancer cell lines.
67 Figure 7b depicts the strong
yellowish light scattering of HY-SGNP as observed
under a dark-ﬁeld microscopy, conﬁrming localization
of particles at the cell surface via receptor-mediated
cell targeting. The ﬂuorescence studies also suggested
that the in vitro uptake of HY-SGNP is comparable to
HY alone (see Fig. 7b). However, in this case, the
ﬂuorescence intensity measured from the nanosensi-
tizer may not truly represent the uptake quantity due
to a possible ﬂuorescence quenching of hypercin mol-
ecules close to the SGNPs.
79 Ongoing studies are
underway to optimize the loading of HY onto the
nanoconstruct for enhanced PDD.
Photothermal Therapy
Nanometer-sized gold particles are known to exhibit
surface plasmon resonance (SPR) eﬀect that is absent
in bulk gold. This plasmonic feature makes GNPs
eﬃcient in generating heat in the presence of electro-
magnetic radiation.
21 At SPR frequency, the strongly
absorbed radiation is converted into heat by electron–
phonon and phonon–phonon processes.
26 The parti-
cles thus serve as heating elements that lead to elevated
temperature of the surrounding medium and induce
hyperthermia or irreversible thermal damage to the
targeted tissue, thereby offering an alternative cancer
treatment called photothermal therapy (PTT).
32,95 A
study showed that the heat conversion efﬁciency of
GNPs increases with their size.
21 In addition, aspect
ratio of the GNRs can be tailored to operate PTT
within the optical window between 700 and 900 nm,
where light penetration in tissue is optimal due to
minimal absorption by water and hemoglobin in the
tissue
95; consequently, the excitation light can reach
deeper tissues and induce PTT. More importantly,
recent studies suggest that PDT and PTT can poten-
tially be merged for efﬁcient cancer treatment.
31,41,67
Controlled Drug Release for PDT
The photothermal heating can further be exploited
to release drug that is loaded onto the GNPs. Photo-
activated release of PS was demonstrated using a
GNR–PS complex as elucidated in Fig. 8.
31 Initially,
GNRs quench the ﬂuorescence emission of PS mole-
cules that are in close proximity (<40 nm)
22 to the
gold surface due to efﬁcient energy transfer from PSs
to GNRs. When irradiated at 810 nm, the photother-
mal heating generated by GNRs liberates the PS from
FIGURE 7. (a) Illustration of a nanoconstruct consists of PS molecules (C11PC) for PDT, PEG for increased stability, and antibody
for cancer-targeting. (Reproduced with permission of Photochemical & Photobiological Sciences
84.) (b) Comparison of HY ﬂuo-
rescence intensity in A-431 cells following incubation with anti-EGFR conjugated HY-SGNP and HY alone. The inset shows the
dark-ﬁeld images of the cells targeted by the particles. (Reproduced with permission of SPIE Proceedings
67.).
MALINI et al. 468the surface to undergo PDT in response to a second
excitation at 670 nm. The PDT efﬁcacy can thus be
photothermally controlled by manipulating the dis-
tance between the PSs and GNRs.
Multimodality Imaging
There are other features of gold nanostructures that
are worthy of mention. These gold nanostructures
often possess high scattering cross sections and are able
to enhance the weak Raman signal of molecules.
Though HY ﬂuorescence is more commonly studied,
its Raman characteristics should not be ignored as the
Raman signal is detectable when the HY molecules are
suﬃciently close to the gold surface which induces
surface-enhanced Raman scattering (SERS).
24 A study
has shown that a joint ﬂuorescence and SERS mea-
surement of HY can facilitate the understanding of its
biological activity.
54
While PSs are useful in giving molecular contrast in
ﬂuorescence and SERS imaging, the gold nanostruc-
tures serve as additional optical contrast agent in other
structural imaging such as optical coherence tomog-
raphy (OCT)
27 and two-photon luminescence.
113 In
particular, OCT, a biopsy-free imaging, is being used
for in vivo clinical applications.
5,19,57 The advantage of
OCT is its ability to provide cross-sectional images of
tissue with high spatial resolution by measuring the
optical echoes backscattered from tissue.
27 Currently,
much effort is put to further develop OCT toward
acquisition of histologically equivalent images for
deﬁnitive diagnosis without the need of biopsies. The
contrast in OCT image is highly dependent on the
microscopic differences in scattering properties across
the tissue layers. However, the early onset of tissue
abnormalities barely changes the tissue optics that
result in poor morphological contrast between normal
and abnormal tissues in OCT images.
38,40 To overcome
these limitations, gold nanostructures, along with
being utilized as a PS carrier, are used to increase the
diagnostic and analytic capabilities of OCT by site-
speciﬁc labeling of tissue of interest. The plasmonically
active nanostructures, such as GNPs,
40,48 GNRs,
92
nanoshell
55, and nanocages,
8 can be optically tuned to
speciﬁcally scatter the OCT probe beam. The key idea
is simply to use OCT to demarcate the abnormal sites
at which these light-scattering particles are targeted.
Though this concept was demonstrated using rigid
OCT probe, there are several groups
1,36,47,110 working
on miniaturization of OCT system that can potentially
be merged with existing ﬂuorescence endoscopy. For
example, Mu et al.
98 have developed a microelectro-
mechanical systems (MEMS)-based OCT catheters to
perform a rapid 3D volumetric scanning. This MEMS-
OCT probe has an outer diameter of only 4 mm and
encloses a patented MEMS micromirror as the optical
steerer. One can envision that such technique com-
bined with molecular imaging is powerful for improved
diagnosis and informative monitoring of tissue struc-
tures during PDT or PTT. Hence, combining
advancements in PDD and nanotechnology offers the
opportunity to signiﬁcantly impact future strategies
toward improved multimodality therapeutics and
imaging.
CONCLUSION
We have investigated the combined use of HY and
state-of-the-art optical techniques for detecting early
cancer, with improved diagnostic accuracy in com-
parison with the standard clinical practice. The stan-
dard diagnosis, which relies on WLE, lacks the ability
in identifying early and ﬂat lesions, and thus runs the
risk of giving false negative results. HY used with
novel optical techniques provides an alternative to
detect the subtle structural and molecular changes
expressed during the development of cancer.
We began by discussing the increased uptake of HY
in progressively invasive cancer cell lines and biopsies.
The tumor selectivity of HY, especially in bladder
cancer, makes it a suitable ﬂuorescent contrast agent in
diﬀerentiating the scattered cancerous sites from the
surrounding healthy tissues. These ﬂuorescence prop-
erties were ﬁrst exploited in ex vivo ﬂuorescence urine
cytology. Unlike tissue sampling, the cell yield in urine
cytology is rather limited, and the presence of con-
taminants in urine could complicate the ﬂuorescence
analysis. Image processing techniques were applied to
get around the problem. Meanwhile, the diagnostic
information from each single cell was also maximized
FIGURE 8. Illustration of photo-activated release of PS
(AIPcS4). PDT is prohibited before photothermal heating of
GNR. Irradiation at 810 nm results in photothermal heating
that releases PS from the GNR. The liberated PS molecules
thereafter undergo PDT action in response to excitation at
670 nm (Reproduced with permission of ACS Nano
31.).
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the microscopic diagnosis with HY was extended to
macroscopic level using FE. FE was employed to
diagnose bladder and oral cavity in situ. With the use
of appropriate camera and optics elements, a single
shot of ﬂuorescence image was adequate to perform a
real-time PDD without the need for a slow ﬂuores-
cence spectral measurement. Fluorescence diagnosis
could be automated and visual aid was provided to
clinicians for a ﬂuorescence-guided biopsy or resection
of tumor. PDD was further developed by incorporat-
ing a CLE for probing the HY intensity at different
tissue depths. In addition, ﬂuorescence images col-
lected at different focal planes were processed to render
a 3D visualization from which more detailed infor-
mation about the lesion morphology could be assessed.
While the ﬂuorescence properties of the HY have
been well exploited in PDD, we discuss about the
underlying trend of coupling HY with the nanotech-
nology for combined therapeutics and multimodality
imaging. The use of gold nanostructures not only
enhances the targeted delivery of HY to cancer cells,
but also serves as a heating element to trigger PTT as
well as providing optical contrast for other optical
imaging techniques. Meanwhile, the photoheating of
GNPs was utilized to manage the release of HY from
nanoconstruct, thus controlling the PDT eﬃcacy; such
approach may carry high potential for modulating
PDT and PTT. Apart from enhancing molecular con-
trast with HY, the nanoparticles serve as complimen-
tary contrast agent when used with other novel optical
imaging modalities, such as two-photon luminescence
imaging, dark-ﬁeld microscopy, OCT, and SERS.
With the continual eﬀort in this ﬁeld, we envision a
successful integration of PSs and multifunctional
nanoparticles to realize informative diagnosis followed
by a multifaceted therapy in near future.
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